ClinicalTrials.gg
RecruitingNCT07257094Updated Jul 9, 2026

Nasal Reconstruction FACE-Q : French Validation of the Nasal Reconstruction FACE-Q Questionnaire for Reconstruction/Rehabilitation Following Nasal Skin Cancer

An observational study in Carcinoma, sponsored by Hôpital NOVO. Recruiting at 9 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Hôpital NOVO · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
346
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Carcinoma with a site in France — 20 open to participants now, 32 under way, 14 of them phase 3. Carcinoma · France.

Planned enrollment
6th of 19
346 · median 279
Started
2026
with 7 others
Observational
19 of 105
7 open now
Primary completion
2027-07
later than 16 of 31 live
Registered
100th of 105
by date

Among the 105 studies in Carcinoma with a site in France, this one is the 6th largest by planned enrollment of the 19 observational ones that give a count, is one of 8 that started in 2026, is one of 19 observational ones, reaches primary completion later than 16 of the 31 other live ones, and was the 100th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

20 of the 105 studies in Carcinoma with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Carcinoma with a site in France, or all of them as a file.
02

Study summary

This study aims to validate a French version of the Nasal Reconstruction FACE-Q questionnaire for patients who have undergone nasal reconstruction or prosthetic rehabilitation after surgery for nasal skin cancer. The questionnaire evaluates appearance, quality of life, and possible side effects related to the reconstruction.

The investigators hypothesize that the validated French version will provide a reliable and standardized tool to assess patient satisfaction and health-related quality of life in this context.

Read the detailed description

Nasal skin cancers often require surgical excision that can result in significant tissue loss. Treatment may involve complex surgical reconstruction or, in some cases, prosthetic rehabilitation. These procedures may have major aesthetic, functional, and psychological consequences.

FACE-Q is an internationally recognized, patient-reported outcome instrument designed to assess satisfaction with appearance, health-related quality of life, and treatment-related adverse effects. However, FACE-Q was developed and validated in English and requires cultural and linguistic adaptation for reliable use in French-speaking populations.

This non-interventional, multicenter study aims to translate and validate the relevant FACE-Q Aesthetics scales in French for patients who have undergone nasal reconstruction or prosthetic rehabilitation after skin cancer. The selected domains address facial and nasal appearance, psychosocial well-being, social function, satisfaction with outcomes, and procedure-related adverse effects.

The expected outcome is to provide a standardized and validated French-language tool that reliably evaluates these patients' satisfaction and quality of life. Such a tool may be applied in clinical practice and future comparative research to improve patient care.

03

Conditions studied

  • Carcinoma

Keywords

  • Basal Cell carcinoma
  • Squamous Cell carcinoma
  • Rhinectomy
  • Reconstructive Surgical Procedures
  • Prosthesis Implantation
  • FACE-Q
  • Quality of Life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients / Controls

Eligibility criteria

PATIENTS

Inclusion Criteria

  • Age ≥ 18 years
  • Patient who has undergone excision of a cutaneous, mucocutaneous, or vestibular nasal cancer with surgical reconstruction using a flap or prosthetic rehabilitation, performed more than 4 months ago, with stable results, and less than 3 years ago
  • Patient informed of the study and not opposed to participation

Exclusion Criteria

  • Patient under anticoagulant or antiplatelet therapy Non-French-speaking patient
  • Patient under legal protection (e.g., guardianship, legal safeguard) or with limited legal capacity
  • Patient unlikely to cooperate with the study and/or poor anticipated compliance as judged by the investigator (including psychiatric disorders other than depressive disorder or cognitive impairment)
  • Pregnant or breastfeeding woman

CONTROL

Inclusion Criteria

  • Age ≥ 65 years
  • Subject informed and not opposed to participating in the study
  • Subject who has never undergone facial trauma or surgery, and without major comorbidity, defined as follows:
  • No heart failure (moderate or severe heart failure, history of heart attack within the last 6 months);
  • No severe chronic respiratory disease (no stage III-IV , no prolonged oxygen therapy);
  • No uncontrolled diabetes or associated severe complications;
  • No active diseases or high-dose immunosuppressive treatment;
  • No unstable or severe facial dermatological conditions;
  • No comorbidities seriously affecting quality of life or respiratory function (at the investigator's discretion).

Exclusion Criteria

  • Non-English speaking subject
  • Subject under guardianship or legal protection, legally incompetent or with limited legal capacity
  • Subject unlikely to cooperate in the study and/or anticipated low cooperation by the investigator (particularly those with psychiatric disorders other than depression or cognitive disorders)
  • Pregnant or breastfeeding women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
346 participants (estimated)
Patient registry
No

Groups and cohorts

  • Operated patients

    Patients with skin cancer in the nasal region who have undergone surgical reconstruction using a flap or rehabilitation using a prosthesis.

    Other: operated patients

  • Control

    Patients with no history of surgery or facial trauma

    Other: Control

Interventions

  • Otheroperated patients

    Response to the Nasal Reconstruction FACE-Q questionnaire, which includes the following scales : * Appearence : Face overall, nose, nostrils, skin * Health related quality of life (HRQOL) : Early life impact, psychological, social, outcome * Adverse effects : on the nose, on the forehead, eyebrows and scalp * Nasal Obstruction Symptom Evaluation (NOSE) * Short-Form-36 (SF 36)

  • OtherControl

    Response to the Nasal Reconstruction FACE-Q questionnaire, which includes the following scales : * Appearence : Face overall, nose, nostrils, skin impact psychological, impact social, * SF36

06

What researchers measure

Primary outcomes

  1. Psychometric validation of the French version of Nasal Reconstruction FACE-Q

    Test the acceptability, reliability, construct validity, and sensitivity to change of the questionnaire.

    Time frame: 7 days

Secondary outcomes

  1. Assessment of the post operative functional satisfaction

    Evaluation of postoperative functional satisfaction using the Nasal Obstruction Symptom Evaluation (NOSE) questionnaire, which measures the severity of nasal breathing obstruction. Correlations will then be calculated between the NOSE and each of the FACE-Q.

    Time frame: 7 days

07

Study locations

4 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.

Of 50 non-industry observational studies under Carcinoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29. This study's planned 18 months is below that.

Counting every sponsor, half of 62 studies reached it within 49 months; a quarter within 29 and three quarters within 166.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 2, 2025
StartActual
Jan 10, 2026
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07257094
Lead sponsor
Hôpital NOVO
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Jan 10, 2026
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Jul 9, 2026

Study contacts

Khaled AL TABAA, Doctor
study director · Hôpital NOVO

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion